XML 35 R12.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Intangibles, Net and Goodwill
 6 Months Ended
Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangibles, Net and Goodwill
6. Intangibles, Net and Goodwill
 Intangibles, Net
Finite-lived Intangible Assets
As of June 30, 2024, the Company's finite-lived intangible assets consisted of acquired ARIKAYCE R&D and the milestones paid to PARI for the license to use the Lamira® Nebulizer System (Lamira) for the delivery of ARIKAYCE to patients as a result of the US Food and Drug Administration (FDA) and EC approvals of ARIKAYCE in September 2018 and October 2020, respectively. The Company began amortizing its acquired ARIKAYCE R&D and PARI milestone-related intangible assets in October 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years. Amortization of these assets during each of the next five years is estimated to be approximately $5.1 million per year.
Indefinite-lived Intangible Assets
As of June 30, 2024, the Company's indefinite-lived intangible assets consisted of acquired IPR&D from the Business Acquisition (see Note 16 - Acquisitions). Indefinite-lived intangible assets are not amortized.
A rollforward of the Company's intangible assets for the six months ended June 30, 2024 and June 30, 2023 is as follows (in thousands):
Intangible AssetDecember 31, 2023AdditionsAmortization
June 30, 2024
Acquired ARIKAYCE R&D$32,738 $— $(2,425)$30,313 
Acquired IPR&D29,600 — — 29,600 
PARI milestones1,366 — (101)1,265 
$63,704 $— $(2,526)$61,178 
Intangible AssetDecember 31, 2022AdditionsAmortizationJune 30, 2023
Acquired ARIKAYCE R&D$37,588 $— $(2,425)$35,163 
Acquired IPR&D29,600 — — 29,600 
PARI milestones1,568 — (101)1,467 
$68,756 $— $(2,526)$66,230 
Goodwill
The Company's goodwill balance of $136.1 million as of June 30, 2024 and December 31, 2023, resulted from the August 2021 Business Acquisition. See Note 16 - Acquisitions for further details.